



BriteBio, Inc. Awarded a Phase I SBIR Grant For the Development of Toxicological Platforms utilizing Human Pluripotent Cells

RESEARCH TRIANGLE PARK, NC BriteBio Inc. announced today the awarding of a Phase I Small Business Innovation Research (SBIR) Grant from the National Institute of Environmental Health Sciences (NIEHS), a division of the National Institutes of Health (NIH). This grant will support to developing a novel, robust, and comprehensive platform for toxicological risk assessment utilizing donor-specific pluripotent cells.

Currently, toxicological risk assessment lacks direct estimation of the magnitude and variability of human responses to environmental toxicants. Specifically, there is very little data on the effects of low dose toxicants on human developmental processes, including cellular differentiation. That is because the current basis of toxicological assessment, animals and immortalized cell lines, cannot adequately model the impact of low level toxicant exposure on human population. A potential alternative detection platform should enable incorporation of human variability in screening of a large number of toxicants in a high-throughput manner. The overall goal of this research is to evaluate the effect of chemical toxicants on viability, proliferation, and differentiation of endothelial progenitor cells or endothelial colony forming cells (ECFCs) derived from different individuals. Specifically, this proposal will determine the feasibility of ECFCs as a platform for high-throughput chemical toxicity testing.

This grant is collaboration between BriteBio, Inc., and Creative Scientist, LLC. John W. Ludlow, Ph.D., BriteBio's Chief Scientific Officer, will be the Principal Investigator. Alexander Kinev, Ph.D., CEO of Creative Scientist, will be the Co-PI.

About BriteBio, Inc.

BriteBio is a woman owned small business formed in 2012 by Dr. Renee Lea-Currie. The mission is to provide the highest quality human cell systems, reagents and contract services to researchers; to develop and commercialize innovative research tools, leverage in-house expertise through research and development and strategic alliances that accelerate discovery.

For more information, contact:

Will Plentl, Director of Business Development

BriteBio, Inc.

infomation@britebio.com

www.britebio.com

####